JP Morgan Chase
EWTX icon

JP Morgan Chase’s Edgewise Therapeutics EWTX Stock Holding History

JP Morgan Chase’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,100
Closed -$904K – 7243
2025
Q1 		$904K Buy
+41,100
New +$1.08M ﹤0.01% 4421

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase's EWTX Position: Q2 2026 in Review

JP Morgan Chase increased its Edgewise Therapeutics (EWTX) stake by 38% in Q2 2026, buying an estimated $1.92M and bringing the position to 203,151 shares worth $8.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2960.

JP Morgan Chase first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • JP Morgan Chase held 203,151 shares of Edgewise Therapeutics worth $8.48M as of Q2 2026.
  • JP Morgan Chase bought 55,578 Edgewise Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Edgewise Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2960 holding.
  • JP Morgan Chase first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.